On April 21, 2026 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulating payloads, reported that its abstract has been accepted for online publication at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This marks Akari’s first abstract acceptance at ASCO (Free ASCO Whitepaper), one of the most highly regarded forums in clinical oncology research, and represents a significant milestone for the Company as it continues to advance its AKTX-101 ADC into Phase 1 clinical development by late 2026/early 2027.
Details are as follows:
Abstract Title: Combination synergy of spliceosome modulator ADC with a K-Ras inhibitor in KRAS–mutated pancreatic cancers
Date and Time: The full publication will be made available on May 21, 2026, at 5:00 PM ET on the ASCO (Free ASCO Whitepaper) website.
"This first ASCO (Free ASCO Whitepaper) acceptance for Akari is continued validation of our novel RNA splicing modulator payload platform for ADCs, and its broad potential in treating a wide range of cancer tumors, including those with KRAS mutations, a rapidly expanding therapeutic category moving forward," said Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. "We believe this data highlights a growing body of evidence demonstrating that targeting RNA splicing in cancer cells could be a powerful way to attack even the most difficult cancers."
Additional details will be disclosed in accordance with ASCO (Free ASCO Whitepaper) embargo policies.
For more information about the ASCO (Free ASCO Whitepaper) Annual Meeting 2026, please visit asco.org.
(Press release, Akari Therapeutics, APR 21, 2026, View Source [SID1234664594])